Genocea Biosciences (GNCA) Tops Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to Genocea Biosciences (GNCA) Tops Q3 EPS by 7c
November 5, 2015 7:30 AM EST
- Company Reports Recent Milestones and Announces Expansion of ATLASTM
Technology into Immuno-Oncology -
- Conference Call and Webcast Scheduled for 9:00 a.m. ET Today -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company
developing T cell-directed vaccines and immunotherapies, today reported
recent corporate highlights and financial results for the third quarter
ended September 30, 2015.
In early... More
November 5, 2015 7:00 AM EST
- Goal is to Utilize ATLASTM to Discover Biologically
Relevant Neoantigens for Vaccine Development -
- Company to Discuss Collaboration and Oncology Strategy on Third
Quarter 2015 Earnings Call at 9am ET Today -
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company
developing T cell-directed vaccines and immunotherapies, today announced
a collaboration with Memorial Sloan Kettering Cancer Center to screen
the T cell responses of melanoma and non-small cell lung cancer patients
treated with checkpoint inhibitors (CPI) against the complete repertoire
of patient-specific putative... More
